by Stren & Blan Partners | Apr 2, 2026 | Health and Pharmaceutical
Nigeria’s health and pharmaceutical sector closed Q1 2026 at a critical turning point, with the quarter marked by notable clinical milestones that signal bigger structural change across the industry, including the introduction of West Africa’s first...
by Stren & Blan Partners | Mar 17, 2026 | Health and Pharmaceutical
Nigeria’s healthcare and pharmaceutical sectors stand at a pivotal moment. An overwhelming demand for quality healthcare services is rising, local drug manufacturing is gaining policy support, and private capital is increasingly interested in the sector’s long-term...
by Stren & Blan Partners | Feb 4, 2026 | Health and Pharmaceutical, Insight
This Stakeholders’ Report provides a comprehensive analysis of key regulatory developments and legislative changes affecting Nigeria’s health and pharmaceutical sector during the year 2025 (the “Report Period”). The report focuses on regulatory advancements that...
by Stren & Blan Partners | Dec 31, 2025 | Health and Pharmaceutical, Insight
Q4 2025 marks an important period for Nigeria’s health and pharmaceutical sector. It is no longer just about introducing new reforms, but about strengthening what has already been put in place, expanding it, and earning global confidence.While Q3 focused on setting up...
by Stren & Blan Partners | Nov 24, 2025 | Health and Pharmaceutical, Insight
Nigeria’s shift from a voluntary health insurance scheme to a mandatory national system under the National Health Insurance Authority (NHIA) Act represents one of the most consequential transformations in the country’s healthcare financing landscape. For decades, the...
by Stren & Blan Partners | Oct 14, 2025 | Health and Pharmaceutical, Insight
The third quarter of 2025 was a notable period in Nigeria’s health and pharmaceutical trajectory, characterised by a sequence of reforms designed to enhance structural efficiency and restore investor confidence. Central to this evolving transformation was the...
